Pharmaceuticals, Inc. Alnylam Net Worth

The estimated Net Worth of Pharmaceuticals, Inc. Alnylam is at least $24 Milion dollars as of 23 February 2016. Pharmaceuticals Alnylam owns over 1,000,000 units of Regulus Therapeutics Inc stock worth over $7,540,943 and over the last 12 years Pharmaceuticals sold RGLS stock worth over $16,421,935.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Pharmaceuticals Alnylam RGLS stock SEC Form 4 insiders trading

Pharmaceuticals has made over 10 trades of the Regulus Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Pharmaceuticals sold 1,000,000 units of RGLS stock worth $7,180,000 on 23 February 2016.

The largest trade Pharmaceuticals's ever made was selling 1,000,000 units of Regulus Therapeutics Inc stock on 23 February 2016 worth over $7,180,000. On average, Pharmaceuticals trades about 198,267 units every 49 days since 2012. As of 23 February 2016 Pharmaceuticals still owns at least 4,896,716 units of Regulus Therapeutics Inc stock.

You can see the complete history of Pharmaceuticals Alnylam stock trades at the bottom of the page.

What's Pharmaceuticals Alnylam's mailing address?

Pharmaceuticals's mailing address filed with the SEC is 300 THIRD STREET, 3RD FLOOR, , CAMBRIDGE, MA, 02142.

Insiders trading at Regulus Therapeutics Inc

Over the last 12 years, insiders at Regulus Therapeutics Inc have traded over $78,282,075 worth of Regulus Therapeutics Inc stock and bought 65,288,007 units worth $66,275,578 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, Regulus Therapeutics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $890,488. The most recent stock trade was executed by Kathryn J Collier on 25 July 2024, trading 4,000 units of RGLS stock currently worth $7,280.

What does Regulus Therapeutics Inc do?

regulus therapeutics inc. (nasdaq:rgls) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting micrornas. regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microrna therapeutics pipeline complemented by a maturing micromarkerssm biomarkers platform and a rich intellectual property estate to retain its leadership in the microrna field. regulus is developing rg-101, a galnac-conjugated anti-mir targeting microrna-122 for the treatment of chronic hepatitis c virus infection, and rg-012, an anti-mir targeting microrna-21 for the treatment of alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. in addition, rg-125, a galnac-conjugated anti-mir targeting microrna-103/107 for the treatment of nash in patients with type 2 diabetes/pre-diabetes, has entered phase i clinical development through its strategic alliance with astrazeneca. reg

Complete history of Pharmaceuticals Alnylam stock trades at Regulus Therapeutics Inc

Regulus Therapeutics Inc executives and stock owners

Regulus Therapeutics Inc executives and other stock owners filed with the SEC include:

• Joseph Hagan,
  President, Chief Executive Officer, Director
• Joseph P. Hagan M.B.A.,
  Pres, CEO & Director
• Christopher Aker,
  Senior Vice President, General Counsel
• Christopher Ray Aker J.D.,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Crispina Calsada,
  Chief Financial Officer
• Crispina Calsada,
  Chief Financial Officer
• Stelios Papadopoulos,
  Independent Chairman of the Board
• Pascale Witz,
  Independent Director
• Simos Simeonidis,
  Independent Director
• Hugh Rosen,
  Independent Director
• William Rastetter,
  Independent Director
• Jake Nunn,
  Independent Director
• Kathryn Collier,
  Independent Director
• David Baltimore,
  Independent Director
• Denis Drygin,
  Chief Scientific Officer
• Firuz Shakoori,
  Head of CMC
• Turner Jenkins,
  Sr. Director of Corp. Devel.
• Dr. Denis Drygin Ph.D.,
  Chief Scientific Officer
• Daniel J. Penksa,
  Controller & Principal Accounting Officer
• Jason Raleigh Nunn,
  
• Daniel R. Chevallard,
  Chief Financial Officer
• Paul C Grint,
  President & CEO
• Douglas E Williams,
  Director
• Mark Albert Deeg,
  Chief Medical Officer
• Pharmaceuticals, Inc. Alnylam,
  10% owner
• Mark G Foletta,
  Director
• Timothy Michael Wright,
  Chief R & D Officer
• Alexander J Sarissa Capital...,
  
• Plcastrazeneca Ab Astrazeneca,
  
• David Leslie Szekeres,
  Chief Business Officer & GC
• Paul Edward Walker,
  
• Peter J Barris,
  10% owner
• Anthony A. Jr. Florence,
  
• Scott D Sandell,
  
• David M Mott,
  10% owner
• Mohamad Makhzoumi,
  
• Equity Opportunities V, Llc...,
  
• Ali Behbahani,
  
• Neil W Gibson,
  Chief Scientific Officer
• Pharmaceuticals Incparshall...,
  
• Kleanthis G Xanthopoulos,
  President and CEO
• Pharmaceuticals Inc Ionis,
  10% owner
• Bruce L A Carter,
  Director
• Barry E Greene,
  Director
• Sanofi,
  10% owner
• B Lynne Parshall,
  Director
• Stanley T Crooke,
  Director
• John Maraganore,
  Director
• Garry E Menzel,
  COO & Executive VP, Finance
• Forest Baskett,
  
• Carmen Chang,
  
• Joshua Makower,
  
• Peter W. Sonsini,
  
• Capital Offshore Master Fun...,
  10% owner
• Alice Shih Hou Baltimore Da...,
  
• Alice Shih Hou Huang,
  
• Preston Klassen,
  President & Head of R & D